A structure-designed peptide pulled apart two copies of a surface receptor and stopped multiple myeloma plasma cells from forming tumors in a chick egg. The receptor is junctional adhesion molecule A (JAM-A), the surface protein encoded by F11R on chromosome 1q. The peptide is one candidate ("P4") out of a rationally designed panel reported online May 27 in the European Journal of Haematology ↗, and it sits on a target that just got elevated into the formal high-risk multiple myeloma framework.
The cytogenetic update that took effect in 2025 added gain or amplification of chromosome 1q to the panel of lesions that define high-risk multiple myeloma. Patients with high-risk disease have shorter survival despite the field's recent additions of CD38 antibodies, proteasome inhibitors, and BCMA cell therapies. F11R lives on that chromosome arm. In the CoMMpass database of newly diagnosed multiple myeloma patients, F11R expression was significantly higher in the gain/amp(1q) subgroup and correlated with shorter overall survival. The gene tracks the cytogenetic lesion, and the cytogenetic lesion tracks the outcome.
It also tracks something more granular. Elevated F11R came with a higher burden of circulating CD138-positive cells, the marker that identifies plasma cells in blood. Extramedullary disease, where myeloma escapes the bone marrow and seeds soft tissue, is one of the worst prognostic features in the disease, and a rising circulating-plasma-cell count is one of its early hallmarks. The biomarker line is the kind of detail that turns a target-validation paper into a screening hypothesis. F11R-high patients may be the ones to watch for extramedullary escape.
The mechanism is geometric. JAM-A signals through cis-dimerization. The receptor pairs with another copy of itself on the same cell surface, and the paired interface relays the adhesion signal that promotes tumorigenic behavior. The structure-based rational design here did not target the JAM-A ligand-binding face. It targeted the homodimer interface. The team designed a panel of peptides intended to selectively disrupt cis-dimerization, screened them across a panel of multiple myeloma cell lines and primary CD138-positive cells drawn from patient samples, and watched the cells stop proliferating and slip into senescence. Candidate P4 came out on top.
The in vivo readout used the chick chorioallantoic membrane xenograft, a model where CD138-positive plasmacytoma-like tumors are seeded onto the vascularized membrane of a fertilized chicken egg and grown for days. P4 significantly inhibited tumor growth in that model. The chick chorioallantoic membrane model is not a mouse, and the readout is short-term, but it does what mouse xenografts often cannot for this disease: preserve the soft-tissue plasmacytoma morphology that JAM-A signaling helps drive. The authors frame this as preclinical proof of concept, not a candidate for the clinic.
What this changes for someone working on peptides. Cis-dimerization disruptors are an underused interface in plasma cell biology. JAM-A sits on the 1q lesion that defines the worst-prognosis cytogenetic stratum in multiple myeloma, and there is no approved drug pointed at it. A small peptide that disrupts the homodimer interface, hits primary patient plasma cells in vitro, and reduces tumor mass in a vascularized soft-tissue model gives the high-risk myeloma field something it has not had: a translational lead designed against the protein the chromosomal lesion appears to act through. The candidate sits at the start of a long development path, but the path begins on a target that matches the prognostic update.